Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abilify MyCite vs Virtual Controls in Schizophrenia, Bipolar 1, and MDD
NCT03643159Phase 4Terminated
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Jun 2018
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of aripiprazole in schizophrenia, bipolar I disorder, major depressive disorder (MDD), sponsored by Otsuka Pharmaceutical Development & Commercialization. Started Jun 2018; status: terminated.
02
Drugs
aripiprazole
03
Conditions
schizophreniabipolar I disordermajor depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03643159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03643159.